Brian Kearney

Brian Kearney's work experience is as follows:

- Current: Chief Development Officer (CDO) at Capacity Bio since September 2023.

- Current: Chief Scientific Officer at Exavir Therapeutics since July 2023.

- Current: Founder at Devs Bio since June 2023.

- Senior Advisor at Medicines Development for Global Health from January 2018 to present.

- Former: Chief Development Officer (CDO) at Pardes Biosciences from October 2020 to May 2023.

- Former roles at Gilead Sciences:

- VP, Clinical Research, Inflammation from May 2020 to October 2020.

- Global Filing Lead, Inflammation (filgotinib) from February 2019 to October 2020.

- Vice President, Clinical Pharmacology from January 2016 to February 2019.

- Vice President, Clinical Research; Head, Clinical Pharmacology from August 2014 to January 2016.

- Sr. Director, Clinical Research from August 2008 to July 2014.

- Global Filing Lead, HCV (sofosbuvir) from April 2012 to December 2013.

- Global Integrated Product Development Lead, HIV (EVG, COBI, EVG/COBI/FTC/TDF combination) from June 2008 to August 2012.

- Global Product Development Lead (cobicistat, COBI) from February 2008 to August 2012.

- Global Product Development Lead (elvitegravir, EVG) from March 2005 to August 2012.

- Director, Clinical Research from March 2007 to August 2008.

- Associate Director, Clinical Pharmacology from March 2003 to February 2007.

- Sr. Research Scientist, Pharmacokinetics and Clinical Pharmacology from March 2000 to February 2003.

- Research Scientist, Drug Delivery and Metabolism from July 1999 to February 2000.

Brian Kearney's education history includes a Post-doctoral Research Fellowship in the Drug Research Unit at the University of California, San Francisco from 1997 to 1999. Prior to that, they were a Resident at the University of Pittsburgh from 1996 to 1997. Brian obtained their PharmD degree from the University of Illinois Chicago from 1990 to 1996.